Terbinorm 250mg 14 tablets — Made in Romania — Free Delivery

Fungal infections of the skin and nails caused by trichophyton (eg t. rubrum, t. mentagrophytes, t. verrucosum, t. violaceum), microsporum canis and epidermophyton floccosum. dermatophytosis lesions of the smooth skin of the trunk, perineum and feet, when the localization of the lesion, the severity or prevalence of the infection determine the appropriateness of oral therapy. onychomycosis.

Application

The preparationis intended for oral use. adults are prescribed 1 tablet (250 mg) 1 time per day. the duration of treatment depends on the nature and severity of the disease.

Skin infections. Recommended duration of treatment:

The complete disappearance of symptoms of infection may occur only a few weeks after the absence of pathogens is detected using laboratory control.

Onychomycosis. The duration of treatment for most patients is from 6 weeks to 3 months. Treatment periods of less than 3 months are possible for patients with lesions of fingernails, toenails other than the thumb, or for younger patients. In the treatment of toenail lesions, 3 months is usually sufficient, although some patients may require therapy for 6 months or longer. Patients requiring longer treatment are identified by a reduced rate of nail growth during the first weeks of treatment. The complete disappearance of symptoms of infection may occur only a few weeks after the absence of pathogens is detected using laboratory control.

Patients with impaired liver function. Terbinorm tablets are not recommended for use in patients with chronic or active liver disease.

Patients with impaired renal function. The use of Terbinorm tablets in patients with impaired renal function has not been adequately studied and is therefore not recommended for this group of patients.

Elderly patients. There is no evidence that elderly patients need to change the dose of the preparation or that they have manifestations of adverse reactions that differ from those in younger patients. In this age group, when using the preparation, the possibility of impaired liver or kidney function should be considered.

Children. Data on the use of the preparation in children are limited, so its use is not recommended in patients of this age group.

Hypersensitivity to terbinafine or any auxiliary component of the preparation.

To assess the frequency of occurrence of various adverse reactions, the following classification was used: very often (≥1/10); often (≥1/100, 1/10); infrequently (≥1/1000, 1/100); rarely (≥1/10,000, 1/1000); very rarely (1/10,000), the frequency is unknown (cannot be established from the available data).

On the part of the blood and lymphatic system: very rarely - neutropenia, agranulocytosis, thrombocytopenia; frequency unknown - anemia, pancytopenia.

From the immune system: very rarely - anaphylactoid reactions (including Quincke's edema), skin and systemic lupus erythematosus; frequency unknown - anaphylactic reactions, reactions similar to symptoms of serum sickness.

From the side of metabolism and nutrition: very often - loss of appetite.

On the part of the psyche: the frequency is unknown - anxiety and depressive symptoms secondary to taste disorders.

From the nervous system: often - headache; infrequently - a violation of the sense of taste, including loss of taste, usually recovers after a few weeks after stopping the preparation. Very rarely, long-term disturbance of taste has been reported, sometimes leading to a decrease in food intake and a significant decrease in body weight; rarely - paresthesia, hypesthesia, dizziness; frequency unknown - anosmia, including constant anosmia, hyposmia.